Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE GORSE-LAVANANT : revenue, balance sheet and financial ratios

PHARMACIE GORSE-LAVANANT is a French company founded 22 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PLEYBER-CHRIST (29410), this company of category PME shows in 2025 a net income positive of 248 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE GORSE-LAVANANT (SIREN 448466508)
Indicator 2025 2024 2023
Revenue N/C N/C N/C
Net income 248 424 € 246 221 € 29 738 €
EBITDA N/C N/C N/C
Net margin N/C N/C N/C

Revenue and income statement

In 2025, PHARMACIE GORSE-LAVANANT generates positive net income of 248 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2025: 30 k€ -> 248 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

248 424 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 75%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

12.511%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

74.682%

Solvency indicators evolution
PHARMACIE GORSE-LAVANANT

Sector positioning

Debt ratio
12.51 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent

In 2025, the debt ratio of PHARMACIE GORSE-LAVANANT (12.51) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
74.68% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent +7 pts over 3 years

In 2025, the financial autonomy of PHARMACIE GORSE-LAVANANT (74.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Positioning of PHARMACIE GORSE-LAVANANT in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE GORSE-LAVANANT is estimated at 3 946 244 € (range 2 677 940€ - 6 192 201€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
2677k€ 3946k€ 6192k€
3 946 244 € Range: 2 677 940€ - 6 192 201€
NAF 5 année 2025

Valuation method used

Net Income Multiple
248 424 € × 15.9x = 3 946 245 €
Range: 2 677 940€ - 6 192 201€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE GORSE-LAVANANT with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE GORSE-LAVANANT

What is the revenue of PHARMACIE GORSE-LAVANANT ?

The revenue of PHARMACIE GORSE-LAVANANT is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMACIE GORSE-LAVANANT profitable?

Yes, PHARMACIE GORSE-LAVANANT generated a net profit of 248 k€ in 2025.

Where is the headquarters of PHARMACIE GORSE-LAVANANT ?

The headquarters of PHARMACIE GORSE-LAVANANT is located in PLEYBER-CHRIST (29410), in the department Finistere.

Where to find the tax return of PHARMACIE GORSE-LAVANANT ?

The tax return of PHARMACIE GORSE-LAVANANT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE GORSE-LAVANANT operate?

PHARMACIE GORSE-LAVANANT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.